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Abstract: Diagnosis of transmissible spongiform encephalopathies (TSEs), or prion diseases, is based
on the detection of proteinase K (PK)-resistant PrPSc in post-mortem tissues as indication of infection
and disease. Since PrPSc detection is not considered a reliable method for in vivo diagnosis in
most TSEs, it is of crucial importance to identify an alternative source of biomarkers to provide
useful alternatives for current diagnostic methodology. Ovine scrapie is the prototype of TSEs and
has been known for a long time. Using this natural model of TSE, we investigated the presence
of PrPSc in exosomes derived from plasma and cerebrospinal fluid (CSF) by protein misfolding
cyclic amplification (PMCA) and the levels of candidate microRNAs (miRNAs) by quantitative PCR
(qPCR). Significant scrapie-associated increase was found for miR-21-5p in plasma-derived but not in
CSF-derived exosomes. However, miR-342-3p, miR-146a-5p, miR-128-3p and miR-21-5p displayed
higher levels in total CSF from scrapie-infected sheep. The analysis of overexpressed miRNAs in
this biofluid, together with plasma exosomal miR-21-5p, could help in scrapie diagnosis once the
presence of the disease is suspected. In addition, we found the presence of PrPSc in most CSF-derived
exosomes from clinically affected sheep, which may facilitate in vivo diagnosis of prion diseases,
at least during the clinical stage.
Keywords: extracellular vesicle; prion; PMCA; cerebrospinal fluid; plasma; bioassay
1. Introduction
Transmissible spongiform encephalopathies (TSEs) are fatal neurodegenerative dis-
eases that affect humans and animals [1]. TSEs result from misfolding of a native cellular
prion protein (PrPC) to an infectious and pathological conformation (PrPSc) in a self-
propagating reaction [2]. Ovine and caprine scrapie was the first TSE described and is
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considered the prototype of these diseases [3]. As in other TSEs, like bovine spongiform
encephalopathy in cattle or variant Creutzfeldt-Jakob disease (vCJD) and Kuru in humans,
in natural scrapie, prions enter the body through infection of the gastrointestinal tract, then,
accumulate in the lymphoreticular system and access the enteric nervous system (ENS)
that seems to be the entry to neural tissues [4]. To date, the precise mechanisms that explain
prion spread to the central nervous system (CNS) are still not well known.
Post-mortem detection of PrPSc in the brain tissue of diseased individuals is used
as a biochemical marker for the presence of infection and disease [5]. However, the use
of this protein as an effective diagnostic biomarker is not considered a reliable method
for in vivo diagnosis since the presence of PrPSc is minimal in accessible tissues and body
fluids such as blood or urine [6]. In addition, new protease-sensitive PrPSc isoforms have
been discovered that are not detectable by current diagnostic methods [7,8]. Therefore, it
is necessary to identify biomarkers other than PrPSc that can be detected from accessible
tissues or fluids to provide useful alternatives for current diagnostic methodology.
Exosomes are small vesicles surrounded by membrane with a variable size ranging
from 30 to 150 nm [9]. These particles are secreted by cells and have been found in body
fluids such as urine, breast milk, saliva, blood or cerebrospinal fluid (CSF) [9]. Exosomes,
originated from endosomes, are released by cells and can reprogram surrounding or distant
cells after selective taking up [10]. The exosomal “cargo”, the vesicular content of proteins,
lipids, non-coding RNAs, mRNAs and microRNAs (miRNAs), can be different according
to the exosome origin. They contain membrane transport and fusion proteins, tetraspanins
and heat-shock proteins that are used as positive markers for exosome characterisation [11].
In vitro studies have demonstrated the release of PrPC and infectious PrPSc by different
types of infected cells in association with exosomes [12–15], suggesting a potential role of
these particles in intercellular transmission, prion spreading and neuroinvasion, although
different prion strains might use the exosomal pathway with different efficiencies [16]. The
release of exosomes in prion diseases seems to be related with the autophagic process.
Blocking autophagy in prion infected neuronal cell cultures boosts release of prions in
exosomes and increases intercellular spread of prion infection [17]. Autophagy process is
impaired in clinical scrapie [18], so this alteration could promote exosome production and
release to biofluids in vivo.
The presence of PrPC among the protein cargo of blood circulating exosomes has
been demonstrated in humans [19] and sheep [20]. PrPSc was first detected by protein
misfolding cyclic amplification (PMCA) in extracellular vesicles (EV) isolated from blood
plasma of mice infected with mouse-adapted vCJD [21] and from 263K scrapie-infected
hamsters [22]. Besides the demonstration of infectivity of exosomes isolated from these
prion-inoculated murine models, to our knowledge, the potential of extracellular vesicles
to mediate pathological prion infectivity has never been described in the natural disease,
even though attempts to detect the presence of the PrPSc in plasma-derived exosomes have
been carried out in natural scrapie sheep using Western blot [20]. More sensitive techniques
such as PMCA or murine bioassays could elucidate if plasma exosomes harbour aberrant
prion protein in natural scrapie.
Brain pathophysiology is reflected in CSF and the presence of EV in this biofluid
represents a potential source of biomarkers for neurological diseases [23]. The levels of
PrPC in CSF have been considered to be a potential biomarker for several neurodegenerative
diseases [24], including ovine scrapie [25], as its concentration seems to decrease in CJD
affected individuals [26,27]. It has been reported that ovine CSF-derived exosomes are
enriched in PrPC [28] but, to our knowledge the presence of PrPSc in EV from CSF has not
been previously described.
The interest of exosomes in TSEs is not limited to the determination of PrPSc, which
could facilitate diagnosis and be crucial for prion transmission. Proteins and microRNAs
(miRNAs) are molecular constituents of exosomes and promising biomarkers for many
diseases, including neurodegenerative diseases [29,30]. Exosomes released in vitro by
prion-infected neuronal cells have altered miRNAs profiles compared to non-infected
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exosomes [31]. In a previous work, we demonstrated the alteration of circulating miRNAs
in plasma of scrapie-infected sheep [32]. In this study, elevated levels of miR-342-3p and
miR-21-5p were found in plasma. However, if these potential biomarkers of prion disease
are free in plasma or included in the exosomal fraction is still unknown.
The relevance of exosomes in prion diseases has only been analysed in vitro and in
murine models of TSE. The aim of this work was to analyse exosomes from blood and
CSF in sheep naturally infected with scrapie, as an animal model of prion diseases. First,
we evaluated the presence of PrPSc (proteinase K-resistant abnormal PrP, also known
as PrPres) by PMCA, which would facilitate in vivo diagnosis. Then, their infectivity or
ability to spread disease in the CNS was evaluated by bioassay. Finally, as the miRNA
profile in exosomes could change with the pathological status of the individual, the potential
of exosomes as a source of biomarkers was evaluated analysing the levels of candidate
miRNAs described to be altered in different prion diseases and their models. These included
miR-342 [31–34], miR-21 [31,34], miRNAs of let-7 family [15,31,35], miR-146a [31,34–37],
miR-494 [33] and miR-128 [31,38].
2. Results
2.1. Exosome Isolation and Characterisation
We successfully isolated exosomes from plasma and CSF using two commercial kits
(miRCURYTM Exosome Isolation Kit (Exiqon, Düsseldorf, Germany) and Total Exosome
Isolation Kit (Invitrogen, Waltham, MA, USA)). Exosomes were visualised using trans-
mission electron microscopy (TEM). Figure 1A shows the presence of small spheres with
diameters between 30 and 120 nm in samples obtained from CSF, using both isolation
kits. According to the MISEV2018 guidelines [39], hereafter we will refer to these vesicles
smaller than 200 nm as small extracellular vesicles (sEVs).
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Figure 1. (A) Characterisation of sEVs derived from cerebrospinal fluid by transmission electron
microscopy (TEM). Images show the presence of small spheres smaller than 200 nm, obtained with
Invitrogen isolation kit (left, 100 nm bar) and Exiqon isolation kit (right, 200 nm bar). (B) Charac-
terisation of sEV derived from blood plasma by dynamic light scattering (DLS). Graph shows that
vesicles isolated from plasma displayed a mean diameter ranging between 30 and 120 nm. Intensity
profiles showed that the major sEV population was approximately 50–120 nm in diameter (Invitrogen
kit) and a second minor population was approximately 20–50 nm (Exiqon miRCURY kit).
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Consistently, dynamic light scattering (DLS) assays showed that vesicles isolated
from plasma displayed a mean diameter ranging between 30 and 120 nm (Figure 1B). DLS
intensity profiles showed that the major sEV population obtained with Invitrogen kit was
approximately 50–120 nm in diameter. Size of the particles obtained with Exiqon miRCURY
kit was smaller, with a peak in approximately 30 nm. The amount of sEVs isolated from
CSF was not sufficiently high for the analysis by DLS.
2.2. Detection of PrPres in sEVs by PMCA
PMCA allows amplification of minimal amounts of pathological prion protein. We
performed this technique with isolated sEVs using brain homogenate from Tg338 transgenic
mice expressing the ovine VRQ prion allele as a substrate [40]. A total of 24 sEV samples
derived from plasma and obtained with Invitrogen kit were analysed by PMCA. After
four successive rounds of PMCA, no proteinase K (PK)-resistant abnormal PrP could be
detected by Dot blot or Western blot in any sample, whereas the brain homogenate from
scrapie sheep included on each run to check the amplification performance displayed
positivity in reactions seeded with a 10−7–10−8 dilution, suggesting that the presence of
PrPres in plasma-derived sEVs, if any, is at least 8 log10-fold lower than that detected in
sheep brains (Figure S1).
On the contrary, after four rounds of PMCA, PrPres was detected in reactions seeded
with CSF-derived sEVs (obtained with Invitrogen kit) in six out of eight samples from
clinically affected sheep and three out of three samples from sheep at terminal stage
(Figure 2A and Figure S2). However, PrPres was detected only in one out of six sEV samples
obtained from CSF of preclinical scrapie sheep. No PrPres signal was detected in reactions
seeded with CSF-derived sEVs from the negative control sheep, confirming the specificity
of the technique. The Western blot electrophoretic PrPres pattern observed after PMCA am-
plification was indistinguishable from that observed in the brain homogenate from scrapie
sheep, displaying a PrPres molecular signature consistent with classical scrapie prions
characterised by a three-banded pattern with a 21 kDa unglycosylated band (Figure 2B).
Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 4 of 16 
 
 
Figure 1. (A) Characterisation of sEVs derived from cerebrospinal fluid by transmission electron 
microscopy (TEM). Images show the presence of small spheres smaller than 200 nm, obtained with 
Invitrogen isolation kit (left, 100 nm bar) and Exiqon isolation kit (right, 200 nm bar). (B) Character-
isation of sEV derived from blood plasma by dynamic light scattering (DLS). Graph shows that 
vesicles isolated from plasma displayed a mean diameter ranging between 30 and 120 nm. Intensity 
profiles showed that the major sEV population was approximately 50–120 nm in diameter (Invitro-
gen kit) and a second minor population was approximately 20–50 nm (Exiqon miRCURY kit). 
Consistently, dynamic light scattering (DLS) assays showed that vesicles isolated 
from plasma displayed a mean diameter ranging between 30 and 120 nm (Figure 1B). DLS 
intensity profiles showed that the major sEV population obtained with Invitrogen kit was 
approximately 50–120 nm in diameter. Size of the particles obtained with Exiqon miR-
CURY kit was smaller, with a peak in approximately 30 nm. The amount of sEVs isolated 
from CSF was not sufficiently high for the analysis by DLS. 
2.2. Detection of PrPres in sEVs by PMCA 
PMCA allows amplification of minimal amounts of pathological prion protein. We 
performed this technique with isolated sEVs using brain homogenate from Tg338 trans-
genic mice expressing the ovine VRQ prion allele as a substrate [40]. A total of 24 sEV 
samples derived from plasma and obtained with Invitrogen kit were analysed by PMCA. 
After four successive rounds of PMCA, no proteinase K (PK)-resistant abnormal PrP could 
be detected by Dot blot or Western blot in any sampl , whereas the brain homogenate 
from scrapie sheep included on each ru  to check the amplification perf rmance dis-
played positivity in reactions seeded with a 10−7–10−8 dilution, suggesting that the presence 
of PrPres in plasma-derived sEVs, if any, is at least 8 log10-fold lower than that detected in 
sheep brains (Figure S1). 
On the contrary, after four rounds of PMCA, PrPres was detected in reactions seeded 
with CSF-derived sEVs (obtained with Invitrogen kit) in six out of eight samples from 
clinically affected sheep and three out of three samples from sheep at ter inal stage (Fig-
ure 2A and Figure S2). However, PrPres was detected only in one out of s x sEV samples 
obtained from CSF of preclinical scrapie sheep. No PrPres sig al was detected in r actions 
seeded with CSF-derived sEVs from the negative control sheep, confirming the specificity 
of the technique. The Western blot electrophoretic PrPres pattern observed after PMCA 
amplification was indistinguishable from that observed in the brain homogenate from scra-
pie sheep, displaying a PrPres molecular signature consistent with classical scrapie prions 
characterised by a three-banded pattern with a 21 kDa unglycosylated band (Figure 2B). 
 
Figure 2. Detection of the pathologic prion protein (PrPSc/PrPres) by Dot blot (A) and Western blot (B) in PMCA reactions 
seeded with serially diluted (1/5, 1/10 and 1/50) CSF-derived sEVs obtained from scrapie-affected sheep. Immunodetection 
was performed using the monoclonal Sha31 antibody. (A) Representative images of PrPres detection by Dot blot after four 
PMCA rounds of CSF-derived sEVs from one sheep at clinical stage of scrapie, one sheep at terminal stage, one sheep at 
Figure 2. Detection of the pathologic prion protein (PrPSc/PrPres) by Dot blot (A) and Western blot (B) in PMCA reactions
seeded with serially diluted (1/5, 1/10 and 1/50) CSF-derived sEVs obtained from scrapie-affected sheep. Immunodetection
was performed using the monoclonal Sha31 antibody. (A) Representative images of PrPres detection by Dot blot after
four PMCA rounds of CSF-derived sEVs from one sheep at clinical stage of scrapie, one sheep at terminal stage, one
sheep at preclinical stage and one negative sheep. A brain homogenate from scrapie sheep (10−3 to 10−9 diluted) is also
shown for comparison. Some dots were subjected to Western blot for PrPres profile detection. (B) Representative images of
PrPres detection by Western blot after four PMCA rounds of CSF-derived sEVs from one sheep at clinical stage of scrapie
(1/10 dilution), one sheep at terminal stage (1/10 dilution), one sheep at preclinical stage (1/50 dilution), one negative sheep
(1/10 dilution) and a brain homogenate from scrapie sheep (10−6 and 10−7 dilution). A proteinase K-digested classical
scrapie isolate (Dawson strain) was used as positive control.
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2.3. Evaluation of sEV Infectivity
CSF and CSF-derived sEVs from one negative control sheep (animal ID: O-1341) and
two scrapie-infected sheep (animals ID: O-941 and O-1682) were also tested for infectivity
by bioassay in Tg338 transgenic mice. A total of 27 mice were intracerebrally inoculated:
nine mice with CSF-derived sEVs obtained with Exiqon kit, nine mice with CSF-derived
sEVs obtained with Invitrogen kit and nine mice with total CSF. In each group, three mice
were inoculated with CSF or CSF-derived sEVs from the negative control sheep and six
mice with CSF or CSF-derived sEVs from the aforementioned two positive scrapie sheep.
Most animals were sacrificed by end point criteria (from 232 days post inoculation
(dpi) of a mouse inoculated with scrapie CSF to 647 dpi of a mouse inoculated with negative
CSF) or at the end of the study. Three of the mice inoculated with CSF-derived sEVs isolated
with the Exiqon miRCURY kit died without showing symptoms compatible with scrapie
or any other end point criteria at ages older than 381 dpi.
The post-mortem PET-blot analysis did not reveal any presence of PrPSc in any inoc-
ulated mice (Figure S4) and no significant differences were observed in haematoxyline-
eosine staining tissue sections of mice inoculated with sEVs obtained from scrapie and
control sheep.
2.4. miRNA Profiles in Plasma-Derived sEVs
We recently described alterations in miRNA profile in plasma from scrapie-infected
sheep [32]. In the present work, we analysed the same set of miRNAs in sEVs isolated from
plasma of sheep naturally infected with scrapie. Nine miRNAs were successfully amplified
in plasma sEVs by qPCR and, of these, miR-21-5p was present in a significantly higher level
(p < 0.05) in sEVs obtained from scrapie-infected sheep (Figure 3). Additionally, miR-146a
showed a tendency for upregulation but this did not reach statistical significance (p = 0.065).
As a general observation, the dispersion between samples was greatly increased in scrapie
sheep compared with controls.
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Figure 3. miRNA profiles in plasma-derived sEVs. Fold-change of miRNAs in sEVs derived from
blood plasma of scrapie sheep (blue circles) compared with control sheep (black squares) as measured
by qPCR. Nine miRNAs were found at detectable levels. Significantly increased levels were found for
miR-21-5p (p < 0.05). Data are expressed as a relative expression value after 2−∆∆Ct conversion using
the mean of healthy control sheep as a calibrator, +/− standard deviation (SD). Statistical significance
was assessed by Student’s t-test (* p < 0.05). The Exiqon kit was used for sEVs purification.
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2.5. miRNA Profiles in CSF and CSF-Derived sEVs
Six miRNAs were successfully amplified in CSF (Figure 4A) with a Ct value lower
than 34, which was set as a limit for reliable detection. Four of these (i.e., miR-342-3p,
miR-146a-5p, miR-128-3p and miR-21-5p) displayed a level significantly higher (p < 0.05)
in CSF from scrapie-infected sheep compared to healthy control sheep (Figure 4A; see also
Figure S3 for difference in Ct values between the control and scrapie samples presented
in Figure 4A). Moreover, miR-132-3p was detected in four out of six scrapie CSF whereas
it was only present in extremely low levels in one control (Figure S3). Levels of only
two of the tested miRNAs were sufficient for quantification in sEVs derived from CSF.
miR-486-5p was present in relatively high levels consistent with the previously published
data suggesting exosomal enrichment of this miRNA [41]. miR-342-3p was present in low
levels and not detectable in all samples (Figure 4B). No significant changes were detected
in sEV miRNAs between scrapie and control samples.
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i l i c tra ficking et ee it i l ll ll
fi in vivo. Bl od has been shown to contain dis ase-associated PrPSc in n tur lly
and experimentally infected sheep [45–48], and in humans infected with vCJD [49,50].
Moreover, PrPSc has been detected in EV preparations containing exosomes from plasma of
mice infected with mouse-adapted prions by PMCA, suggesting that exosomes may have a
relevant role in carrying PrPSc in blood [51]. Here, the presence of the pathological form
of the protein in plasma-derived sEVs has been investigated in the natural prion disease.
We isolated sEVs using commercial kits and the presence of sEVs in the precipitate was
confirmed by TEM. After four rounds of PMCA, no PrPres could be detected in any sample
Int. J. Mol. Sci. 2021, 22, 6822 7 of 16
of plasma derived sEVs, whereas the original brain homogenate displayed positivity in
a 10−7 to 10−8 dilution, suggesting that the presence of PrPSc of plasma-derived sEVs,
if any, is at least 8 log10-fold lower than that detected in sheep brains. Therefore, the
detection of PrPSc by PMCA in these vesicles does not represent a useful tool for natural
scrapie diagnosis.
On the other hand, ovine CSF-derived sEVs seem to be enriched in PrPC [28], but
the presence of PrPSc in these vesicles has not been described. In this work, we detected
the pathological form of the protein in CSF-derived sEVs after four rounds of amplifi-
cation, in six out of eight samples from clinically affected sheep and three out of three
samples from sheep at terminal stage. Unfortunately, PrPSc was detected only in one out of
six sEV samples obtained from CSF of preclinical scrapie sheep, which limits its use for
early diagnosis of prion diseases. Despite positive results from PMCA, infectivity of these
particles was not observed in vivo. We used precipitation-based kits to isolate the sEVs,
which could interfere the ability of PrPSc infection in vivo. On the other hand, we did not
quantify the amount of the exact numbers of sEVs inoculated and a dose adjustment could
be necessary for in vivo bioassays.
Exosomes can serve as a source of biomarkers. MicroRNAs are small RNA molecules
that produce a post-transcriptional regulation of target genes [52]. They are present in
exosomal cargo and it seems that loading of miRNAs into exosomes is not a random
process [53]. Altered miRNA profiles in CSF or blood exosomes associated with neurode-
generative disorders have revealed new biomarkers in the diagnosis of Alzheimer’s disease
(AD) [30,54], amyotrophic lateral sclerosis [29] or Parkinson’s disease [55]. We investigated
here the potential of circulating sEVs for the diagnosis of ovine scrapie.
miRNA profiles are changed in the CNS of different TSE models [36,38] and in brains
from CJD patients [33,37]. In a previous work, we identified two altered miRNAs in plasma
from sheep showing clinical signs of scrapie [32]. Here, we analysed in plasma-derived
sEVs the same set of miRNAs that were previously reported to be altered in prion infected
models. We did not observe any enrichment of miRNA levels in sEVs and only the amount
of miR-21-5p differed between control and scrapie plasma. Exosome-shuttling miR-21
has been proposed as a potential biomarker for many diseases including a prognostic
biomarker for oesophageal cancer patients [56], or even as a universal biomarker to identify
cancers [57]. Due to its effects on cardiac contractility and calcium handling, exosomal
miRNA secreted by mesenchymal stem cells have been proposed as possible therapy for
future stem cell-based cardiotherapies [58]. However, neurotoxicity for exosomal miR-
21-5p linked to simian immunodeficiency virus has also been proposed [59]. miR-21-5p
is one of the most abundant miRNAs in several kinds of exosomes and the increase of
this miRNA associated to different cancers could be linked to the increment in exosome
production of cancer cells [60]. It could be plausible that the scrapie-associated increase
observed here is also due to an increment in exosome release linked to the disease and not
to specific packaging of this miRNA by scrapie infected or reactive cells.
Changes in CSF circulating miRNAs have also been associated with different neu-
rodegenerative diseases. For example, miRNA profiles can discriminate AD patients from
healthy controls [61]. Analysing the same set of miRNAs that were studied in plasma, we
show here for the first time a different miRNA profile in CSF of sheep naturally infected
with scrapie. The levels of four miRNAs were significantly increased in scrapie CSF. The
higher number of detected alterations could possibly be expected due to the direct inter-
action between CSF and brain extracellular space. Once again, miR-21-5p appeared to be
upregulated in scrapie. miR-21-5p levels have been shown to be increased, among others, in
CSF of acute encephalitis patients infected with Japanese Encephalitis virus [62], temporal
lobe epilepsy [63] and glioma. Therefore, it must be considered that elevated levels of
miR-21-5p in a wide range of pathologies involving CNS could diminish its usefulness as a
specific biomarker for prion diseases.
MicroRNA miR-342-3p, that was also upregulated in scrapie CSF, have also been found
increased in encephalitis patients [62] but downregulated in plasma from AD patients [64].
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The expression of this miRNA is also increased in brains from CJD patients and altered
in murine models of prion disease, which may be a general phenomenon in the late
stage of prion infection and might be used as a novel biomarker for animal and human
TSEs [33,34]. Our studies, both in plasma and CSF, confirm the potentiality of this miRNA
as scrapie biomarker. On the other hand, the levels of miR-146a-5p augmented in CSF of
AD patients [64]. This miRNA, which is overexpressed in murine brain tissues infected
with prions, seems to modulate microglial activation state [34,36]. However, it has also
been shown to play a role on inflammation, myeloid cell proliferation and oncogenic
transformation [65]. In addition, high levels of miR-128-3p have also been related with
other neuropathologies like acute ischemic stroke [66]. This miRNA is released in exosomes
from prion-infected neuronal cells [31] and targets ATG1 to activate autophagy in brain
cells after ischemia reperfusion [67]. Finally, miR132-3p, which was amplified almost
exclusively in scrapie sheep, regulates neuronal differentiation, maturation and function
and participates in axon growth, neural migration and plasticity [68]. This miRNA is in
significant decline in the CNS of Alzheimer’s patients in late courses of the disease [69]
and in a patient with progressive supranuclear palsy, a tauopathy disorder [70]. On the
contrary, a significant increase of miR-132 has been observed in a rat model of Parkinson’s
disease [71]. An abnormal transcription of miR-132-3p is observed at early phases of
infection of hippocampal CA1 neurons infected with prions [72]. Our results indicate that
this miRNA may play a role in the pathogenesis of prion diseases in vivo.
Isolation of CSF-derived sEVs for further miRNA quantification did not promote
miRNA detection by signal amplification. Only two miRNAs were amplified in levels
sufficient for reliable quantification and no differences were detected between scrapie and
control sEVs. Although the amount of sEVs in CSF was very low, they could be detected
by TEM, showing the expected size. It is possible that the sEV isolation yield could be
improved by concentration of CSF. Although it is difficult to compare levels of miRNAs
in total CSF and CSF-derived sEVs, we used four times the volume of CSF used for RNA
extraction to isolate sEVs. Thus, it appears that, at least for this set of miRNAs, the amount
of free or protein-incorporated CSF miRNAs is much higher than EV-incorporated miRNAs.
This is consistent with previously published RNAse protection assay data that indicate that
many miRNAs, including miR-21, are primarily found outside the exosomal vesicles [73].
This study has several limitations. First, the study of miRNAs was focused on a
small number of miRNAs selected based on the literature and our previous findings in
plasma. Our results encourage further studies focused on whole miRNome in both plasma
and CSF, and not only free miRNAs but also exosomal miRNAs. Unbiased genome-
wide transcriptomics approach would avoid discarding any potential miRNAs of interest
for the development of new diagnostic biomarkers. Second, in the present study, two
methodologies were applied for exosome isolation. Although the protocols for plasma
isolation are relatively well established, exosome extraction from CSF would benefit from
methodological optimisation to facilitate their use for diagnostic purposes.
Taking our results and those of others together, the altered miRNAs analysed in this
work could be biomarkers of brain damage, but they are not specific of prion diseases.
However, the analysis of this battery of miRNAs could help in scrapie diagnosis once the
presence of the disease is suspected. Although the use of CSF is not a choice for scrapie
diagnosis, our results could also contribute to CJD diagnosis. Our findings suggest that the
presence of PrPSc in sEVs derived from CSF may represent a potential source of biomarkers
for TSEs and may facilitate in vivo diagnosis, at least during the clinical stage of the disease.
Further studies are required, involving the amplification of PrPSc also in total CSF to
compare it with that of sEV-enriched fraction to elucidate the potential of CSF-derived sEVs
to be feasible biomarkers, which in the end may contribute to providing useful alternatives
for current TSE diagnosis methodology.
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4. Materials and Methods
4.1. Animals and Sample Collection
A total of 58 sheep were used in this study. Most of them were female Rasa Aragonesa
sheep, aged between 2 and 9 years and displaying the ARQ/ARQ genotype, which is the
most frequently found genotype in scrapie-affected animals of this breed [74]. This group
of animals included 13 negative control sheep, 6 animals at preclinical stage of scrapie
disease, 33 at clinical stage and 6 at terminal stage. Tables S1–S4 show the identification,
breed, sex, PRNP genotype, age, disease status and experimental use of each one of the
animals studied.
Plasma was obtained from 5 mL of blood, which was collected by jugular venipuncture
from each animal. Blood was centrifuged for 10 min at 1300× g at room temperature (RT)
to separate plasma, divided in aliquots and stored at −80 ◦C until analysis. A volume of
approximately 15 mL of CSF was obtained from each sheep immediately after sacrifice,
using a 10 mL syringe inserted into the cisterna magna and avoiding blood contamination.
CSF was also aliquoted and stored at −80 ◦C until analysis.
4.2. Extracellular Vesicle Isolation from Plasma and CSF
Two commercial kits were used for sEV isolation from plasma: Total Exosome Isolation
Kit (from plasma) (Invitrogen, Waltham, MA, USA) and miRCURYTM Exosome Isolation
Kit—Serum and plasma (Exiqon). The initial amount of plasma used for sEV isolation was
250 µL for the first kit and 500 µL for the second one. We followed the manufacturer’s
instructions, with a final resuspension of sEV pellets in 100 µL of PBS (Invitrogen, Waltham,
MA, USA) or 270 µL of Resuspension Buffer (Exiqon). sEVs isolated with the first kit were
subjected to PMCA for PrPSc detection (n = 24), whereas those obtained with miRCURYTM
kit were used for further RNA extraction and miRNA profiling (n = 16).
Total Exosome Isolation Kit (from other body fluids) (Invitrogen) was used for sEV
isolation from CSF for further PMCA analysis (n = 19), and miRCURYTM Exosome Isolation
Kit—Cells, Urine and CSF (Exiqon) was used to isolate sEVs for miRNA profiling (n = 12).
Both kits used a starting sample of 1 mL CSF to precipitate sEVs, with a final resuspension
step in 50–75 µL of PBS (Invitrogen) or 100 µL of Resuspension Buffer (Exiqon). In all cases,
the purified sEV samples were stored at −20 ◦C until their use.
4.3. sEVs Characterisation
4.3.1. Transmission Electron Microscopy
sEV morphology was analysed in two sEV samples obtained from plasma and CSF.
The morphology was evaluated by transmission electron microscopy (TEM) using the
methodology previously described [75,76]. A volume of 5 µL of resuspended sEVs were
fixed in 2.5% glutaraldehyde and then washed with deionised water. Samples were
contrasted with 2% uranyl acetate, embedded in 0.13% methyl cellulose and 0.4% uranyl
acetate, and then visualised using a Tecnai T20 microscope (FEI Company, Hillsboro, OR,
USA), with a filament of LaB6. The voltage used during the visualisation was 200 KV,
and acquiring images was performed with a CCD 2 K × 2 K Veleta model (Olympus,
Tokyo, Japan).
4.3.2. Dynamic Light Scattering
The size distribution of nanoparticles was evaluated using dynamic light scattering
(DLS) assays as previously described [76]. An aliquot of 25 µL of sEV precipitate was
diluted in PBS to a final volume of 500 µL and measured in the NanoBrook 90Plus PALS
Particle Analyzer (Brookhaven Instruments Corporation, Holtsville, New York, USA).
Samples were hit by a diode laser of 35 mW, which allowed discrimination of particle sizes
between 0.3 nm and 6µm.
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4.4. PrPSc Determination by PMCA
Presence of PrPSc in sEVs isolated from plasma (n = 24: 17 scrapie-infected sheep at
clinical stage, 5 at terminal stage and 2 negative controls) and CSF (n = 19: 8 scrapie-infected
sheep at clinical stage, 6 at preclinical stage, 3 at terminal stage and 2 negative controls)
was analysed by PMCA.
PMCA was performed by mixing 5 µL of the seed with 45 µL of substrate per well
in a 96-well PCR microplate (Axygen Scientific, Corning, NY, USA). The PrPC substrate
was prepared from brain tissue (10% brain lysate) of uninfected transgenic Tg338 mice
expressing ovine PrPC in cold PMCA buffer (50 mM tris-HCl, pH 7.4, 5 mM EDTA, 300 mM
NaCl, 1% Triton X-100). One teflon bead (diameter, 2.381 mm) was added to each well.
Each sample was run in duplicate using 1/5, 1/10 and 1/50 dilutions in PMCA buffer.
Amplification was performed in a modified sonicator (QSonica Q700), using a water
recirculation system (39.5 ◦C) [46]. Microplates were then submitted to 96 cycles of 10 s
sonication (75% power) followed by a 14 min and 50 s incubation period. After the first
PMCA round, 5 µL of the reaction product were added to a new microplate containing
45 µL of fresh substrate and a new round of 96 cycles was performed. A total of 4 rounds of
PMCA (24 h each) were performed in this study. To limit the cross-contamination risks that
are linked to serial PMCA, lines of unseeded substrate were included on each microplate
and procedures were performed in different rooms using dedicated material. A 10-fold
dilution series (10−3 to 10−9 diluted) of brain homogenate from ARQ/ARQ ovine scrapie
sheep was included on each PMCA run to check the amplification performance. Brain
homogenates were prepared in PBS (10% weight/volume) from medulla oblongata.
On completion of the PMCA procedure, Dot blot was used to analyse the presence
of PrPSc in each PMCA round. PMCA products (18 µL) were supplemented with 2 µL of
3% SDS and treated with PK (final concentration, 50 µg/mL) for 1 h at 37 ◦C. Digestion
was stopped by adding an equal volume of Laemmli buffer and heating at 95 ◦C for 5 min.
A 5-µL volume of sample was mixed with 25 µL of 1% SDS. The samples were then vacuum
transferred onto a nitrocellulose membrane. The membrane was rinsed once with PBS
(0.1% Tween 20) and incubated for 30 min in PBST containing 2% BSA. The monoclonal
antibody (mAb) Sha31 (1:8000 dilution in PBST + 2% BSA), which recognises residues
145–152 (YEDRYYRE) of PrP, was used for PrPSc/PrPres immunodetection [77]. Antibody
binding was detected by incubating the membranes for 20 min with conjugated mouse
anti-goat IgG (1:5000 dilution; Santa Cruz Biotechnology, Dallas, TX, USA). Immunoblots
were developed by enhanced chemiluminescence using ECL reagent (Pierce, Waltham, MA,
USA) and visualised using the Versa Doc Quantity One image analysis system (Bio-Rad,
Hercules, CA, USA).
TeSeE Western blot kit (Bio-Rad, Hercules, CA, USA) was used following the man-
ufacturer’s recommendations to analyse the presence of PrPSc in the last round of each
PMCA procedure. A volume of 20 µL of PMCA reaction product was mixed with 180 µL of
10% negative brain sheep homogenate before PrPSc extraction, as previously described [46].
PrPSc detection was performed using Sha31 mAb conjugated to horseradish peroxidase
(0.06 µg/mL), and ECL substrate (Pierce) was used to reveal peroxidase activity.
4.5. Bioassay in Tg338 Mice
sEVs isolated from CSF using both commercial kits were stored at 4 ◦C and used
as inocula for the bioassay in transgenic Tg338 mice within the next 48 h. Intracerebral
inoculations were performed under gaseous anesthesia using 50 µL syringes and 25-gauge
hypodermic needles inserted into the right parietal lobe, delivering 20 µL of the inoculum
to each animal. Nine mice were inoculated with CSF-derived sEVs obtained with Exiqon
kit, 9 mice with CSF-derived sEVs obtained with Invitrogen kit and 9 mice with total CSF.
In each group, 3 mice were inoculated with CSF or CSF-derived sEVs from a negative
control sheep and 6 mice with CSF or CSF-derived sEVs from two positive scrapie sheep.
To reduce post-inoculation pain, a subcutaneous injection of buprenorphine (0.3 mg/kg)
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was administered to each mouse before recovery to consciousness. After inoculation, mice
were housed in filtered cages and their clinical status was monitored three times a week.
Histopathological Analysis of Inoculated Mice
Mouse brains were fixed in formalin, embedded in paraffin, cut into 4 µm sections, and
mounted on glass slides for histological evaluation using haematoxylin and eosin staining.
The level of vacuolisation was evaluated in each sample using a semiquantitative score
with a scale of 0 (lack of vacuolisation) to 5 (very high presence of vacuoles). On the other
hand, an analysis of PrPSc deposition was performed using the paraffin-embedded tissue-
blot (PET-blot) method as previously described [78]. Briefly, 4 µm paraffin-embedded
brain sections were collected onto a nitrocellulose membrane and dried at 56 ◦C for 24 h.
Afterwards, the membranes were subjected to dewaxing and rehydration and incubated
for 2 h in a PK solution (250 µg/mL) at 56 ◦C to digest PrPC. The remaining PrPSc was
denatured by incubating the membranes in a solution of guanidine thiocyanate 3 M. After
blocking the membranes with 0.2% BSA, PrPSc was detected using the Sha31 mouse mAb
(1:8000, SPI-Bio) and a secondary alkaline phosphatase-conjugated antibody (1:500, Agilent
Dako). Enzymatic activity was visualised using NBT/BCIP (Thermo Scientific, Waltham,
MA, USA).
4.6. RNA Purification and miRNA Quantification
4.6.1. sEV RNA Extraction
After sEV precipitation from plasma using miRCURYTM Exosome Isolation Kit (n = 16,
8 from healthy and 8 from scrapie-infected sheep), total sEV RNA extraction was carried
out using miRCURYTM RNA Exosome Isolation Kit-Biofluids (Exiqon) following the man-
ufacturer’s recommendations. RNA from CSF-derived sEVs (n = 12, 6 from healthy and 6
from scrapie-infected sheep) was extracted using miRCURYTM RNA Isolation Kit—Cell
and Plant (Exiqon, Düsseldorf, Germany) according to the manufacturer’s recommenda-
tions. In both cases, precipitated sEVs were lysed with the appropriate volume of Lysis
Solution and subsequently spiked in with a 5.7 µL of a carrier/spike solution containing
0.5 µg MS2 RNA and 25 fmol cel-miR-39 and at the end of the process, RNA was eluted to
100 µL Elution Buffer and stored at −80 ◦C for miRNA expression analysis.
4.6.2. Total RNA Extraction from CSF
Total RNA was purified from 200 µL of CSF and 200 µL of CSF after sEV purification
(sEV-depleted CSF) using Total RNA Purification Kit (Norgen, Thorold, ON, Canada)
according to the manufacturer’s instructions. Briefly, the samples were lysed with 600 µL of
Lysis Buffer and carrier/spike solution was added as above. After adding 600 µL ethanol
the lysate was passed through RNA binding columns, the bound RNA was washed and
eluted to 50 µL Elution Solution and stored at −80 ◦C for miRNA expression analysis.
4.6.3. Retrotranscription and miRNA Amplification
Retrotranscription was performed using specific stem-loop TaqMan MicroRNA Assays
(Applied Biosystems, Waltham, MA, USA) for each miRNA and TaqMan MicroRNA Re-
verse Transcription Kit (Applied Biosystems). For each sample, retrotranscription for seven
miRNAs and cel-miR-39, used as a “spike-in” normaliser, was performed in a pooled reac-
tion containing 9 µL of template RNA. The sequence for each miRNA is shown in Table S5.
Individual miRNAs were quantified using the previously described methodology [32,35].
Briefly, qPCR was performed in three technical replicate reactions consisting of 2.5 µL
2× TaqMan Fast Universal PCR Master Mix, no AmpErase UNG (Life Technologies,
Waltham, MA, USA), 0.25 µL TaqMan miRNA Assay probe (Life Technologies, Waltham,
MA, USA) and 2.25 µL of complementary DNA diluted 1:5 in nuclease-free water. Cycling
conditions were 95 ◦C for 20 s followed by 40 cycles of 95 ◦C for 1 s and 60 ◦C for 20 s.
Sample/probe combinations where Ct values exceeded 34 cycles were omitted. For each
sample, the mean Ct of technical replicates for each miRNA was normalised using the
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mean Ct of spiked-in cel-miR-39. Relative miRNA expression was determined with the
2−∆∆Ct method [79] using healthy control sheep as calibrators. Differences between groups
were statistically evaluated using Student’s t-test.
5. Conclusions
Analysis of circulating biofluids could facilitate and/or complement current diagnos-
tic markers for prion disease as these fluids are known to harbour PrPSc and extracellular
miRNAs. To what extent these potential biomarkers may associate with extracellular vesicle
compartment in these biofluids remains largely unknown. Two of the most frequently stud-
ied biofluids in neurodegenerative conditions are CSF and blood plasma. We demonstrated
that PrpSc/PrPres is present in CSF sEVs from scrapie sheep but was not detected in sEVs
from plasma, despite the latter containing more sEVs. The CSF-derived, PrpSc-containing
sEVs did not demonstrate infectivity in vivo. Both plasma and CSF displayed some miRNA
alterations in natural sheep scrapie, the CSF showing increased number of altered miRNA
species. Purification of sEV fraction from the said biofluids did not lead to better detection
levels of studied miRNAs, even if the amount of biofluids used for sEV extraction was
considerably larger. Both the presence of PrPSc and the altered levels of several studied
candidate miRNAs in CSF could facilitate the development of biofluid-based biomarkers
for the prion diseases in the future.
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